dinutuximab beta

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

March, 2025

dinutuximab beta

Jul 24, 2024, 13:28 | Blog

Ruzanna Papyan: The significant role of anti-GD2 therapy in the treatment of relapsed or refractory neuroblastoma

Ruzanna Papyan shared a post on LinkedIn about a recent paper by Patricia Raiser et al., commenting:…

Jul 10, 2024, 05:18 | Insight

APEIRON Biologics to be Acquired by Ligand Pharmaceuticals for USD 100 Million

APEIRON Biologics AG (“APEIRON”), a leading Austrian biotech company, today announced that its shareholders have…

May 27, 2024, 12:01 | Drugs

Ruzanna Papyan: I suggest delving into the critical management of adverse events associated with dinutuximab beta

Ruzanna Papyan shared on LinkedIn: "Week 3 of the Global Access To Anti GD2 Campaign:…

All: 3 Posts: 1 - 100

'

Karen Knudsen has been appointed as the CEO of the Parker Institute for Cancer Immunotherapy

'

Highlights from ELCC 2025

'

FDA Approved Pluvicto (177Lu-PSMA-617) for Metastatic Castration-Resistant Prostate Cancer

'

Meet the New AACR Board of Directores for 2025-2028 Term

'

Do Artificial Sweeteners Cause Cancer? Myths and Facts

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023